ArticleBMC infectious diseases2016
Competitive advantage of a dengue 4 virus when co-infecting the mosquito Aedes aegypti with a dengue 1 virus.
Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Phylogeographic dynamics of oropouche virus in the Colombian Amazon: Evolutionary insights in a climatic context.PLoS neglected tropical diseases · 2026Article
- Review
- The consequence of simultaneous and sequential coinfections ofFrontiers in cellular and infection microbiology · 2026Article
- Dengue virus serotype 4 in Aedes aegypti mosquitoes in Kenya.PLoS neglected tropical diseases · 2025Article
- Intra-vector infection dynamics challenge how to model the extrinsic incubation period for major arboviruses: dengue, Zika, and chikungunya.PLoS computational biology · 2025Article
- Article
- Susceptibility of diverse sand fly species to Toscana virus.PLoS neglected tropical diseases · 2025Article
- Climate, inter-serotype competition and arboviral interactions shape dengue dynamics in Thailand.Communications biology · 2025Article
- Article
- Serotype-specific clinical features and spatial distribution of dengue in northern Kerala, India.Journal of family medicine and primary care · 2024Article
- Phylogenetic Investigations of Dengue 2019-2021 Outbreak in Guadeloupe and Martinique Caribbean Islands.Pathogens (Basel, Switzerland) · 2023Article
- A Maximum Entropy Model of the Distribution of Dengue Serotype in Mexico.Transboundary and emerging diseases · 2023Article
- Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades.Nature communications · 2022Article
- Potential role of vector-mediated natural selection in dengue virus genotype/lineage replacements in two epidemiologically contrasted settings.Emerging microbes & infections · 2021Article
- The effects of DENV serotype competition and co-infection on viral kinetics in Wolbachia-infected and uninfected Aedes aegypti mosquitoes.Parasites & vectors · 2021Article
- Dengue virus in humans and mosquitoes and their molecular characteristics in northeastern Thailand 2016-2018.PloS one · 2021Article
- Trends of the Dengue Serotype-4 Circulation with Epidemiological, Phylogenetic, and Entomological Insights in Lao PDR between 2015 and 2019.Pathogens (Basel, Switzerland) · 2020Article
- Vector competence of Aedes aegypti from New Caledonia for the four recent circulating dengue virus serotypes.PLoS neglected tropical diseases · 2020Article
- Host-shift as the cause of emerging infectious diseases: Experimental approaches using Drosophila-virus interactions.Genetics and molecular biology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue viruses (DENV) are comprised in four related serotypes (DENV-1 to 4) and are critically important arboviral pathogens affecting human populations in the tropics. South American countries have seen the reemergence of DENV since the 1970's associated with the progressive re-infestation by the mosquito vector, Aedes aegypti. In French Guiana, DENV is now endemic with the co-circulation of different serotypes resulting in viral epidemics. Between 2009 and 2010, a predominant serotype change occurred from DENV-1 to DENV-4 suggesting a competitive displacement. The aim of the present study was to evaluate the potential role of the mosquito in the selection of the new epidemic serotype.
methodsTo test this hypothesis of competitive displacement of one serotype by another in the mosquito vector, we performed mono- and co-infections of local Ae. aegypti collected during the inter-epidemic period with both viral autochthonous epidemic serotypes and compared infection, dissemination and transmission rates. We performed oral artificial infections of F1 populations in BSL-3 conditions and analyzed infection, dissemination and transmission rates.
resultsWhen two populations of Ae. aegypti from French Guiana were infected with either serotype, no significant differences in dissemination and transmission were observed between DENV-1 and DENV-4. However, in co-infection experiments, a strong competitive advantage for DENV-4 was seen at the midgut level leading to a much higher dissemination of this serotype. Furthermore only DENV-4 was present in Ae. aegypti saliva and therefore able to be transmitted.
conclusionsIn an endemic context, mosquito vectors may be infected by several DENV serotypes. Our results suggest a possible competition between serotypes at the midgut level in co-infected mosquitoes leading to a drastically different transmission potential and, in this case, favoring the competitive displacement of DENV-1 by DENV-4. This phenomenon was observed despite a similar replicative fitness in mono-infections conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.